Physician profile
Eli Silver
NPI 1740377449
$4,446.43
in general payments reported to CMS, 2019-2025
19 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $95.15 · 2021: $441 · 2022: $920 · 2023: $665 · 2024: $1,033 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170 · Honoraria: $300 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.00 |
| Honoraria | $300.00 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $875.68 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $618.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $613.94 | 2019-2025 | Nucala |
| Kaleo, INC. | $346.11 | 2019-2024 | Auvi-Q |
| Chiesi USA, INC. | $300.00 | 2024 | Revcovi |
| Amgen INC. | $288.45 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $240.38 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $223.57 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $211.74 | 2022 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $152.33 | 2019-2024 | Dupixent |
| Pfizer INC. | $146.97 | 2019-2023 | |
| Ionis Pharmaceuticals, INC. | $66.77 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $39.05 | 2020-2021 | |
| Phadia US INC. | $33.24 | 2019-2023 | Immunocap |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $28.90 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $24.65 | 2023 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $21.46 | 2025 | Alvesco |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.